Cancer Treatment Tolerability Consortium

An image of medical doctors meeting at a table, pointing at an electronic tablet.The NCI Cancer Moonshot Tolerability Consortium is a consortium of multidisciplinary teams that is developing new methods for analyzing patient-reported outcomes in the setting of cancer clinical trials. These methods will better define patient tolerability to cancer treatment.

The tolerability of cancer treatments is a critical element of reducing suffering and death from this disease. In addition to the acute toxicities of treatment, long-term and chronic side effects can both decrease a patient’s ability to complete treatment and greatly affect their quality of life.

This consortium seeks to expand upon the use and reach of the PRO-CTCAE as well as develop more methods to analyze and report.

Read more About the Tolerability Consortium.

Consortium Organization

  • Steering Committee
  • Members
  • NCI/FDA Stakeholders

Learn more about the Consortium Organization

Working Groups

  • GP5
  • Standardization Working Group
  • Common Data Elements

See the Working Groups

Resources and Tools

  • Selected Scoring and Summary Measures
  • Color Schemes
  • Other Resources

Learn more about the Tolerability Consortium's
Resources and Tools


View the Publications


View the Presentations